Vaxart’s Oral Flu Vaccine: Innovation Amid Financial Volatility
Vaxart’s oral flu vaccine could revolutionize flu prevention, but the biotech’s shaky finances and regulatory hurdles keep investors wary.
3 minutes to read
Vaxart Inc
Vaxart’s Oral Flu Vaccine: Innovation vs. Volatile Biotech Market Pressures
Vaxart’s oral flu vaccine could revolutionize flu prevention, yet the biotech’s steep financial struggles and regulatory hurdles keep its future uncertain.
2 minutes to read
Vaxart’s Oral Flu Vaccine Breakthrough: Market, Stock, & Global Impact
Vaxart’s oral flu vaccine harnesses gut immunity to deliver a convenient, potentially superior alternative to injections—transforming flu prevention and biotech investing.
2 minutes to read
Vaxart Inc. Appoints Jeroen Grasman as New CFO Amid Financial Reorganization
Vaxart Inc. has appointed Jeroen Grasman as its new Chief Financial Officer, effective May 19, 2025, as the company navigates financial developments and prepares for future growth.
2 minutes to read